• Earlier in February 2026, Stryker announced two additions to its orthopaedics portfolio: the T2 Alpha Humerus Nailing System for complex humeral fractures and the limited market release of Mako RPS, a handheld robotic system for total knee procedures.
• By extending its Mako robotics franchise into handheld tools and integrating fracture fixation into a unified nailing platform, Stryker is deepening its ecosystem approach to orthopaedic care and hospital workflow efficiency.
• Next, we’ll examine how expanding the Mako robotics platform with the handheld RPS system may influence Stryker’s broader investment narrative.

Outshine the giants: these 24 early-stage AI stocks could fund your retirement.

Stryker Investment Narrative Recap

To own Stryker, you need to believe in its ability to compound growth from a broad, innovation-led orthopaedics and medical technology portfolio, despite regulatory, cost and pricing pressures. The latest T2 Alpha Humerus System and Mako RPS launches reinforce Stryker’s robotics and trauma ecosystems but do not materially change the near term focus on managing supply chain constraints and tariff headwinds that could still weigh on margins.

Among the recent announcements, the limited market release of Mako RPS for Total Knee looks most relevant, as it extends the Mako brand into handheld robotics while staying anchored to existing implant systems and guidance platforms. For investors, this sits squarely within the core catalyst of technology driven procedure adoption, yet it still competes with risks such as reimbursement pressure and delayed European approvals that could affect how quickly new platforms translate into financial results.

But while innovation like Mako RPS can support Stryker’s growth story, prolonged EU MDR approval timelines are a risk investors should be aware of...

Stryker's narrative projects $30.4 billion revenue and $5.4 billion earnings by 2028. This requires 8.4% yearly revenue growth and an earnings increase of about $2.5 billion from $2.9 billion today.

Uncover how Stryker's forecasts yield a $424.40 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Five fair value estimates from the Simply Wall St Community span roughly US$347 to US$424 per share, showing how far apart individual views can be. Against that backdrop, Stryker’s push to expand its Mako robotics ecosystem highlights how product execution and regulatory progress could meaningfully influence how those expectations evolve over time.

Explore 5 other fair value estimates on Stryker - why the stock might be worth as much as 12% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Stryker research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Stryker research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Stryker's overall financial health at a glance.

Want Some Alternatives?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.